Purpose: The purpose of this study was to evaluate the effect of proinflammatory cytokines on the metabolism and survival of chondrocytes obtained from osteochondral allografts (OA) as compared to fresh chondrocytes obtained from human organ donors. Methods: Nine OA specimens (hemicondyle), previously refrigerated for 14-28 days, were collected at the time of surgery and six fresh hemicondyles were obtained from normal donors within 24 hours of death through the Gift of Hope Organ and Tissue Donor Network. 4mm tissue explants from OA and fresh cartilage were cultured in media containing 10% fetal bovine serum and divided into the following treatment groups: 1) culture control (serum only), 2) IL-1β (0.1 ng/ml), 3) IL-6 (3ng/ml), 4) IL-1β (0.1 ng/ml) + IL-6 (3ng/ml), 5) IL-1β (10 ng/ml), 6) IL-1β (10 ng/ml) + IL-6 (3ng/ml). IL-6 soluble receptor (5ng/ml) was added to all cultures containing IL-6. Doses of cytokines were determined based on synovial fluid levels in patients undergoing allograft transplantation. Treatment was administered every other day. Tissue and media were collected on days 0, 2, 7, and 14. Cell viability (live/dead assay), apoptosis (Tunel assay), histological appearance with Safranin O staining, proteoglycan (PG) synthesis and content (normalized to wet weight) were used to analyze cartilage survival and metabolism. Results: At day zero, the viability of OA chondrocytes was 24% lower and they contained 29% more apoptotic cells than fresh chondrocytes (p<0.05). Treatment with cytokines did not further induce cell death or apoptosis in OA cartilage. However, in fresh cartilage, treatment with high dose IL-1 (10ng/ml) alone or in combination with IL-6 showed a significant decrease in chondrocyte viability by day 14 (p<0.05 and p=0.05 correspondingly) as well as a significant increase in the number of apoptotic cells (p=0.05 and p<0.05) when compared to day 0 control. Fresh chondrocytes showed 2.5 times greater PG synthesis (p<0.05) and only half as much release of PGs into the media (p<0.01) when compared to OA chondrocytes at day 0. However, fresh chondrocytes were more sensitive to cytokine treatments: by day 14 high dose IL-1 alone or combined with IL-6 inhibited PG synthesis by more than 8-fold (p<0.02) vs 4-fold in OA cells (p<0.02) and induced higher PG release, which resulted in higher Mankin score for fresh cartilage (1.3 vs 3.0, p<0.04).
Conclusions:
The viability and metabolism of OA cartilage is significantly lower than fresh cartilage; however, OA cartilage is more resistant to cytokine treatment. The reduced metabolism and sensitivity of OA cartilage might explain allograft survival in an acute inflammatory environment (at least short-term) suggesting that OA cartilage may act more like a scaffold rather than an active tissue. Further long-term studies are warranted in order to understand the performance of OA cartilage. Purpose: It is increasingly recognised that the overproduction of mediators such as Nitric Oxide (NO) in Osteoarthritic cartilage contributes to the disease pathology partly by inducing chondrocyte apoptosis via the mitochondrial pathway. Therefore, agents which protect against NO-induced mitochondrial injury may have therapeutic potential in Osteoarthritis (OA). We have previously shown that the human chondrocyte cell line C-20/A4 produces members of the Urocortin (Ucn) family of peptides in response to pro-apoptotic insults and that exogenous administration of all of these peptides protects chondrocytes from NO induced apoptosis with Ucn I being the most potent. The purpose of this study was to elucidate potential mechanisms of action and signalling pathways through which these peptides may exert their effects. Methods: C-20/A4 cells were maintained in monolayer culture in a Dulbecco's MEM (DMEM) -based medium containing 10% foetal calf serum (FCS) at 37°C and 5% CO2. Prior to treatment, cells were transferred to T25 tissue culture flasks, allowed to reach approx. 80% confluency and then serum-starved for 24 hours in DMEM based medium containing 1% FCS and then treated with 1mM SNAP (NO donor) for 6 hours. CRH receptor and KATP channel subunit expression were analysed by RT-PCR. p42/44 MAPK activation was studied by western blotting with antibodies specific for total and phosphorylated p42/44. Apoptotic cell death was assessed by Annexin V/PI binding and TUNEL assay with necrosis assessed by LDH release Results: The addition of Ucn1 to SNAP treated C-20/A4 cells provides protection against apoptosis which is abrogated by the addition of the CRFR antagonist αhCRH suggesting the presence of CRH receptors on these cells the expression of which was confirmed by RT-PCR demonstrating the expression of both corticotropin releasing factor receptors, CRFR1 and CRFR2 mRNA, specifically the CRFR1α and CRFR2β splice variants. Further RT-PCR studies demonstrate the expression of both the Kir and SUR subunits of the mitochondrial ATP sensitive inwardly rectifying potassium channel with western blotting studies indicating a Ucn mediated increase in p42/44 MAPK activation, representing possible mechanisms for Ucn mediated chondroprotection. Conclusions: Studies with αhCRH and RT-PCR analysis for the expression of CRFR receptors indicate the presence of two active forms of the CRF receptors, CRFR1α and CRFR2β on C-20/A4 chondrocytes. The presence of these receptors provides a putative cell surface binding site for Ucn family mem-bers to exert their cytoprotective effects which may be mediated through a mechanism involving Kir 6.1-containing mitochondrial potassium channels, which we have also shown to exist in this cell line. The observation that these cells express both CRFR1 and CRFR2 is novel in that CRFR1 are largely confined to the central nervous system in humans, but would explain the greater potency of Ucn I in chondroprotection as this peptide binds to both CRFR1 and CRFR2 whilst Ucn II and Ucn III are selective CRFR2 ligands. The demonstration that Ucn treatment results in p42/44 MAPK activation also suggest the involvement of other cytoprotective mechanisms (e.g. cAMP and PKA modulated responses) in Ucn mediated chondroprotection. Purpose: NF-kappaB transcription factor regulates several cell signaling pathways, such as differentiation and inflammation, which are both altered in osteoarthritis. IKKalpha and IKKbeta are kinases involved in the activation of the NF-kappaB transcription factor. The aim of the present study was to determine the effects of glucosamine, which is administered in the treatment of osteoarthritis, and of its 2-(N-Acetyl)-L-phenylalanylamido-2-deoxy-beta-D-glucose derivative (glucosamine-derivative) on IKK kinases and, consequently, on NF-kappaB activation in human chondrocytes. Methods: The human chondrosarcoma cell line HTB-94 and human primary chondrocytes were stimulated with TNFalpha after pre-treatment with glucosamine or glucosamine-derivative. Gene mRNA expression level was evaluated by Real Time-PCR. IkappaBalpha phosphorylation and p65 nuclear translocation were analyzed by Western blotting, IKKalpha nuclear re-localization was investigated by immunocytochemistry and by Western blotting. IKK kinase activity was studied by in vitro kinase assay, using IKK complex immunoprecipitated by cells or using recombinant IKkalpha and IKKbeta. Results: After TNFalpha stimulation, the mRNA expression level of some of the genes under NF-kappaB control, such as IL-6 and IL-8, increased, while treatment with glucosamine and glucosamine-derivative reverted the effect. We investigated the possibility that flucosamine and its derivative inhibit IKK kinase activity and found that glucosamine-derivative inhibits the IKKalpha kinase activity, whereas glucosamine does not. Interestingly, both molecules inhibit IKKalpha nuclear translocation. Conclusions: Our results demonstrate that glucosamine and its peptidylderivative can interfere with NF-kappaB signaling pathway by inhibiting IKKalpha activity in human chondrocytes. However, the mechanism of action of the two molecules is not completely overlapping. While glucosamine-derivative can both specifically inhibit the IKKalpha kinase activity and IKKalpha nuclear translocation, glucosamine only acts on IKKalpha nuclear re-localization. Purpose: Chondrocytes become hypertrophic, which leads to calcification of cartilage matrix. This is a pathological event in the early phase of osteoarthritis (OA). We are interested in three subpopulations: pre-hypertrophic chondrocytes, hypertrophic chondrocytes and mature hypertrophic chondrocytes, which are undergoing apoptosis. These three subpopulations of hypertrophic chondrocytes play different role in pathogenesis of OA. The aim of our work was to develop and validate an ex vivo model, which includes the different subpopulations of chondrocytes, and in which hypertrophic chondrocytes could be induced by adding appropriate factors. This model was supposed to be used for examination of cartilage changes related to morphological changes. Thus, aiding the understanding of the role of hypertrophy chondrocytes in OA pathogenesis. Methods: Full depth cartilage explants (from superficial to calcified cartilage) were isolated from bovine femoral condyle and cultured for 21 days with different stimulators: 1) TNF-α [20ng/ml] + Oncostatin M [10ng/ml], 2) IGF-1 [100ng/ml], 3) bFGF [50ng/ml], and 4) BMP-2[100ng/ml]. Supernatants were collected every two or three days. Safranin O/Fast Green (SaFO) and Tuludine Blue (TuB) staining were used to distinguish the morphology of the explants. Collagen type II turnover was measure by PIINP (formation) and CIIMB (degradation) assay. As markers of hypertrophy chondrocytes, expression of Indian hedgehog, type X collagen, ALP and MMP-13 were evaluated using reverse transcription followed by real-time polymerase chain reaction (PCR) at day 14. Results: Alamarblue data showed that all explants were alive throughout the 21 days. Both IGF-1 and bFGF groups had enlarged cells at day 7 and 14 (TuB and SaFO stainings). CIIMB and PIINP assay results suggested that both IGF-1 and bFGF had significant (p<0.05) collagen type II degradation and formation at day 7, but not day 14 and 21. BMP-2 increased significantly expression of Ihh, COL X, ALP and MMP-13 at day 14 (p<0.0001) compared with W/O. bFGF increased expression of Ihh and MMP-13 but not significantly, and the expression of COL X and ALP of bFGF stimulated group were lower than W/O. The increased expression of hypertrophy chondrocytes markers confirmed that BMP-2 could induce chondrocytes hypertrophic in FDC model.
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A FULL-DEPTH CARTILAGE EXPLANTS CULTURE MODEL FOR
Conclusions:
We have developed an explants culture models that include all the different layers of the articular cartilage and were able to induce hypertrophy by stimulating with BMP-2. We could detect the gene expression of markers at different subpopulations of chondrocytes in the ex vivo culture model. We speculate that this model could be used as an important ex vivo model for simulating cartilage degenerative diseases and thereby for investigating the effect of different drug candidates. Purpose: Glucocorticoids are known to attenuate bone formation in vivo leading to decreased bone volume and increased risk of fractures, whereas effects on the joint tissue are not known. This study aimed at characterizing the effect of glucocorticoids on osteoclasts and osteoblasts, as well as the closely related chondrocytes. Methods: We used CD14+ monocytes cultured in the presence of M-CSF and RANKL to investigate the effect of glucocorticoids on different osteoclastic parameters. We measured TRACP activity and Calcium release as indices of osteoclast number and activity. 2T3 preosteoblastic cells we used to characterize the effects of glucocorticoids on bone formation, either in the presence or absence of BMP-2. Alizarin Red was used to measure nodule formation, ALP activity as an indicator of osteoblastogenesis. Bovine full depth cartilage explants were cultured with or without TNF-a, OSM and IGF-1 to characterize the effects of glucocorticoids on cartilage turnover. Collagen type II degradation was measured by CIIMB, and aggrecan degradation by 373-G1. Safranin O staining was used to investigate proteoglycan content in sections of the cultured explants. In all assays Alamar Blue was used as an indicator of viability. Results: DEX and PRED dose-dependently inhibited osteoclastogenesis by promoting cell death. For mature osteoclasts, low doses of GLUC induced bone resorption short term, whereas high doses and continued exposure led to osteoclast death. In osteoblasts glucocorticoids induced cell death in the non-stimulated cells. For BMP-2 stimulated cells; we found that GLUCs augmented nodule formation, while still reducing cell viability. In cartilage we found that GLUCs were unable to alter cartilage turnover, although at high concentrations a minor reduction in safranin O staining intensity was observed. Conclusions: In summary, using highly robust models of bone and cartilage turnover, we have shown that the effects of glucocorticoids on bone depend very much in the cell targeted, i.e. activated osteoblasts are further activated by GLUC, whereas non-activated cells undergo cell death. In cartilage no apparent effects were observed, indicating that cartilage may not possess glucocorticoid receptors, or that these are not active. We believe that these model systems are highly relevant for the continued development of glucocorticoid analogues without the detrimental effect on bone
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